Sentien Biotechnologies said today that it closed a $12 million Series A financing round, co-led by Boehringer-Ingelheim Venture Fund USA, Inc. and BioInnovation Capital. Chiesi Ventures, MBL Venture Capital Co. and Mass Medical Angels also contributed to the round.
The Cambridge, Mass.-based company said it plans to use the funds for initial clinical development of its drug-device combination product, SBI-101.
Get the full story at our sister site, Drug Delivery Business News.
The post Sentien raises $12m Series A for drug-device combo for acute kidney injury appeared first on MassDevice.
from MassDevice http://ift.tt/2nB1Qaj
Cap comentari:
Publica un comentari a l'entrada